February 20, 2017
Faron recruits first patent for Traumakine, a Multi-Organ Failure drug
Faron Pharmaceuticals has recruited first patient in the Phase II INFORAAA clinical trial of Traumakine for the treatment of Multi-Organ Failure (MOF) and mortality prevention of surgically operated Ruptured Abdominal Aorta Aneurysm (RAAA) patients.